<DOC>
	<DOCNO>NCT00637780</DOCNO>
	<brief_summary>This study characterize steady state pharmacokinetics sulfasalazine delay release tablet pediatric Juvenile Idiopathic Arthritis patient . Data study fulfill post approval commitment FDA .</brief_summary>
	<brief_title>Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Sulfasalazine</mesh_term>
	<criteria>Patients diagnosis oligoarticular , polyarticular , psoriatic enthesitisrelated JIA determine ILAR criterion . Patients continuously treat generic sulfasalazine delay release formulation tolerate product least 3 month prior study enrolment switch AzulfidineEN least 8 day prior Day 0 eligible . Patients must least 6 year age reach his/her 18th birthday prior Baseline Visit ( Day 0 ) . Onset JIA must occur prior patient 's 16th birthday . Patients must weigh least 20 kg . Patients must sulfasalazine 500 mg delay release tablet total daily dose must within specify range 3060 mg/kg/day maximum daily dose 3 g/day Patient currently systemic feature systemic JIA . Hypersensitivity sulfasalazine , metabolite , sulfonamide salicylate . History sensitivity heparin heparininduced thrombocytopenia . Inability swallow whole ( uncrushed ) sulfasalazine 500 mg delay release tablet require protocol</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Sulfasalazine delay release tablet</keyword>
	<keyword>azulfidine entabs</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Juvenile Idiopathic Arthritis ( JIA )</keyword>
</DOC>